TG Therapeutics has reported positive topline Phase 1 data for subcutaneous BRIUMVI in patients with myasthenia gravis and has started a potentially registration-directed Phase 2 trial evaluating the therapy as maintenance treatment after induction with efgartigimod. The update marks an important step in the company’s attempt to expand BRIUMVI beyond relapsing forms of multiple sclerosis and into a second autoimmune neuromuscular disease where treatment durability, symptom control, and chronic therapy burden remain major clinical concerns.

The company said 82% of patients in the Phase 1 myasthenia gravis cohort achieved a minimal clinically important difference in Myasthenia Gravis Activities of Daily Living score at Week 24, with a mean 4.6-point improvement. StockTitan reported the clinical update as part of its trial feed, highlighting both the Phase 1 signal and the initiation of the Phase 2 maintenance study. The early data are encouraging, but the clinical significance will depend on whether the findings can be replicated in a larger randomized setting and whether the sequential treatment approach can meaningfully reduce dependence on repeated FcRn inhibitor cycles.

Why subcutaneous BRIUMVI is being tested in myasthenia gravis after multiple sclerosis success

BRIUMVI, also known as ublituximab-xiiy, is already approved as an intravenous anti-CD20 therapy for relapsing forms of multiple sclerosis. TG Therapeutics is now studying whether the same B-cell depletion strategy can be useful in myasthenia gravis, an autoimmune neuromuscular disease in which patients can experience fluctuating muscle weakness affecting the eyes, face, swallowing, speech, breathing, and limb function.

The rationale is clinically plausible because myasthenia gravis is often driven by pathogenic antibodies, including acetylcholine receptor antibodies in many patients. B-cell targeting may therefore offer a way to influence disease biology over time. However, the treatment landscape is not static. FcRn inhibitors and complement inhibitors have already changed expectations in generalized myasthenia gravis by offering targeted approaches that can produce clinically meaningful symptom improvement.

TG Therapeutics is not positioning BRIUMVI simply as another acute symptom-control therapy. The company is testing a sequential strategy in which patients first receive efgartigimod, an FcRn inhibitor associated with rapid clinical benefit, and then move to BRIUMVI as a maintenance therapy intended to sustain response through B-cell depletion. If successful, that approach could create a differentiated clinical model: rapid improvement first, followed by a potentially more durable maintenance phase.

The concept is interesting because chronic FcRn therapy can involve repeated treatment cycles, payer scrutiny, and ongoing patient burden. A maintenance strategy that reduces the need for frequent repeat treatment could be attractive to clinicians and patients, but it must prove that it can maintain disease control without introducing unacceptable safety concerns.

How the Phase 1 myasthenia gravis data support further BRIUMVI development

The Phase 1 data remain early, but the signal is meaningful enough to justify continued investigation. TG Therapeutics said the cohort included 11 acetylcholine receptor-antibody-positive myasthenia gravis patients who received subcutaneous BRIUMVI in dose cohorts that demonstrated exposure at least equivalent to the approved intravenous BRIUMVI regimen. At baseline, patients had clinically meaningful disease burden, with a mean MG-ADL score of 8.24 and a mean Quantitative Myasthenia Gravis score of 12.0.

At Week 24, 82% of patients achieved a minimal clinically important difference in MG-ADL, defined as a decrease of at least two points. The company also reported a median time to MCID of 30 days and a mean 4.6-point improvement in MG-ADL at Week 24. Those findings suggest that subcutaneous BRIUMVI may have clinical activity in myasthenia gravis, although the small sample size limits interpretation.

Safety is equally important. TG Therapeutics said subcutaneous BRIUMVI was generally well tolerated in the Phase 1 cohort, with a safety profile appearing consistent with the established safety profile of intravenous BRIUMVI in multiple sclerosis. That is reassuring as far as it goes, but a small open-label Phase 1 cohort cannot fully characterize safety in a broader myasthenia gravis population.

This distinction matters because anti-CD20 therapy can carry immunologic risks, including infection-related concerns. Myasthenia gravis patients may also have different comorbidities, background therapies, and disease risks than multiple sclerosis patients. Larger controlled studies will therefore be needed to evaluate whether BRIUMVI’s benefit-risk profile remains acceptable in this new setting.

Why the Phase 2 trial design could determine whether BRIUMVI becomes a serious MG contender

The newly initiated Phase 2 trial is the more consequential part of the announcement because it tests the company’s broader treatment hypothesis. The study will evaluate BRIUMVI as maintenance therapy in adults with myasthenia gravis who first respond to efgartigimod induction. According to TG Therapeutics, patients who respond after a single four-dose efgartigimod cycle will be randomized 1:1 to BRIUMVI or placebo for 24 weeks.

The primary endpoint is time to clinical worsening, defined as a two-point or greater increase in MG-ADL from baseline or a myasthenic crisis requiring hospitalization during the randomized treatment period. All patients will then be eligible for a 72-week open-label extension with BRIUMVI. The study is expected to enroll approximately 120 patients.

That design matters because it asks a practical clinical question. Can BRIUMVI maintain the benefit achieved with FcRn inhibition and extend disease control after induction therapy? If the answer is yes, TG Therapeutics could position BRIUMVI as part of a sequential care model rather than as a direct substitute for existing myasthenia gravis drugs. That could make the product clinically distinctive.

However, the trial also creates specific risks. Because all patients first receive efgartigimod, the study must show that BRIUMVI meaningfully extends response beyond what might otherwise occur after induction. The endpoint of time to clinical worsening is clinically relevant, but regulators and clinicians will closely examine the durability, magnitude, and consistency of benefit. They will also want to understand how safety compares with the potential reduction in chronic FcRn treatment burden.

What clinicians will watch as BRIUMVI moves deeper into myasthenia gravis development

For neurologists, the biggest question is whether BRIUMVI can deliver durable disease control in a population that already has several targeted treatment options. The myasthenia gravis field has become more competitive, with therapies aimed at FcRn, complement, and broader immune pathways. Any new entrant must show a clear role in treatment sequencing.

BRIUMVI may have an opening if it can support maintenance after rapid induction. In practice, clinicians often need therapies that act quickly during symptomatic disease but also help keep patients stable over time. A sequential approach could potentially align with that need, especially for patients who respond well to FcRn inhibition but may not want or may not be able to remain on repeated cycles indefinitely.

Still, the approach needs stronger evidence. Phase 1 improvement in 11 patients can generate interest, but it cannot define a treatment paradigm. The Phase 2 trial must demonstrate that the maintenance concept works in a larger, randomized population and that any benefit is clinically meaningful enough to change practice. Regulators may also scrutinize whether the trial can truly be considered registration-directed depending on the strength of results, endpoint performance, safety profile, and trial conduct.

The study’s open-label extension could provide useful long-term data. Myasthenia gravis is a chronic disease, and any therapy intended for maintenance must show durability beyond a few months. Long-term safety, infection risk, immunoglobulin changes, relapse patterns, and retreatment needs may all become important in judging BRIUMVI’s future role.

Why the latest BRIUMVI update is clinically promising but still early

TG Therapeutics has delivered an encouraging early signal in myasthenia gravis, and the initiation of a potentially registration-directed Phase 2 trial gives the program a clearer development path. The company is attempting to combine rapid symptom improvement from FcRn inhibition with longer-term disease control through B-cell depletion, an approach that could be clinically meaningful if validated.

The update also broadens the BRIUMVI story. Until now, the drug has been best understood as a multiple sclerosis asset. Positive data in myasthenia gravis could expand its perceived utility across B-cell-driven autoimmune disease and support TG Therapeutics’ broader pipeline ambitions. That said, the evidence remains preliminary.

The main caution is scale. Eleven patients are not enough to determine efficacy, safety, or commercial relevance. The Phase 2 trial will need to show that the effect is durable, reproducible, and strong enough to justify regulatory consideration. It will also need to show that BRIUMVI can add meaningful value in a field where high-efficacy therapies are already changing standards of care.

For now, the most balanced interpretation is that TG Therapeutics has opened a credible new development path for BRIUMVI in myasthenia gravis. The Phase 1 data support continued study, and the Phase 2 trial gives the company a focused way to test the maintenance-treatment thesis. Whether this becomes a new treatment paradigm will depend on randomized data, regulatory alignment, and evidence that patients can sustain meaningful benefit over time.

  BRIUMVI, efgartigimod, myasthenia gravis, TG Therapeutics, ublituximab-xiiy